tradingkey.logo

Imvigor011 Bladder Cancer Trial Achieves Positive Results, With Signatera™ Strongly Predicting Adjuvant Immunotherapy Benefit

ReutersAug 18, 2025 1:25 PM

Natera Inc NTRA.O:

  • IMVIGOR011 BLADDER CANCER TRIAL ACHIEVES POSITIVE RESULTS, WITH SIGNATERA™ STRONGLY PREDICTING ADJUVANT IMMUNOTHERAPY BENEFIT

  • NATERA INC - SIGNATERA-POSITIVE PATIENTS SHOW IMPROVED SURVIVAL WITH ATEZOLIZUMAB

  • NATERA INC - TO FINALIZE FDA APPLICATION FOR SIGNATERA

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Related Articles

Tradingkey
KeyAI